Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chemotherapy-induced neutropenia

Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND

Patient must be at greater than 20% risk of developing febrile neutropenia; or

Patient must be at substantial risk (greater than 20%) of prolonged severe neutropenia for more than or equal to seven days.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chemotherapy-induced neutropenia

Patient must be receiving chemotherapy with the intention of achieving a cure or a substantial remission; AND

Patient must have had a prior episode of febrile neutropenia; or

Patient must have had a prior episode of prolonged severe neutropenia for more than or equal to seven days.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Mobilisation of peripheral blood progenitor cells

The treatment must be to facilitate harvest of peripheral blood progenitor cells for autologous transplantation into a patient with a non-myeloid malignancy who has had myeloablative or myelosuppressive therapy.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Mobilisation of peripheral blood progenitor cells

The treatment must be in a normal volunteer for use in allogeneic transplantation.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Assisting bone marrow transplantation

Patient must be receiving marrow-ablative chemotherapy prior to the transplantation.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Assisting autologous peripheral blood progenitor cell transplantation

The treatment must be following marrow-ablative chemotherapy for non-myeloid malignancy prior to the transplantation.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe congenital neutropenia

Patient must have an absolute neutrophil count of less than 100 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; AND

Patient must have had a bone marrow examination that has shown evidence of maturational arrest of the neutrophil lineage.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Severe chronic neutropenia

Patient must have an absolute neutrophil count of less than 1,000 million cells per litre measured on 3 occasions, with readings at least 2 weeks apart; or

Patient must have neutrophil dysfunction; AND

Patient must have experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics in the previous 12 months; or

Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic cyclical neutropenia

Patient must have an absolute neutrophil count of less than 500 million cells per litre lasting for 3 days per cycle, measured over 3 separate cycles; AND

Patient must have experienced a life-threatening infectious episode requiring hospitalisation and treatment with intravenous antibiotics; or

Patient must have had at least 3 recurrent clinically significant infections in the previous 12 months.